Getein Biotech: The company sues Jingchuan Diagnostics to exercise shareholder information rights

Getein Biotech announced that the company recently received a "Notice of Case Acceptance" from the People's Court of Wuhan East Lake New Technology Development Zone, and the company has filed a lawsuit against Jingchuan Diagnostics. Getein Biotech acquired a 56.98% stake in Jingchuan Diagnostics through agreement transfer and capital increase in 2020, becoming its controlling shareholder. However, since December 2023, the company has had poor communication with Jingchuan Diagnostics and has been unable to understand its operational situation, while Jingchuan Diagnostics has refused to provide financial data, resulting in the inability to conduct internal audits. The company believes that Jingchuan Diagnostics' actions have severely harmed the company's legitimate rights and interests and violated the disclosure requirements for listed companies, thus requesting to review accounting vouchers, accounting books, and other materials since July 21, 2020. The case has not yet gone to trial, and it is currently impossible to assess the impact on the company's current or future profits